Almirall Aims To Disrupt Actinic Keratosis Space With Klisyri
Gel Gets Backing Of The EMA
Helped by its convenient five-day dosing, the shortest of any topical treatment for the precancerous skin disease, the Spanish company believes Klisyri, already launched in the US, will become a popular alternative to current options for actinic keratosis.
